secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2025-05-27T23:59:59+00:00
Accession:  0001140361-25-020409
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharma announces FDA clinical hold on Phase 2 Danon gene therapy trial after patient death
--------------------------------------------------------------------------------

- Patient in Phase 2 trial of RP-A501 experienced SAE (capillary leak syndrome) and later died due to acute systemic infection.
- FDA placed clinical hold on May 23, 2025; company had voluntarily paused dosing earlier.
- Root cause analysis focusing on novel immune suppression agent added to pre-treatment regimen for complement activation.
- Company unable to provide guidance on trial completion timing.
- Cash $318.2M as of March 31, 2025; expects to fund operations into 2027 with reduced spend.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125020409/0001140361-25-020409-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125020409/ef20049685_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-020409

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer